Gilead Sciences Inc (GILD)
Profitability ratios
Return on sales
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 40.08% | 44.47% | 46.08% | 47.80% | 39.27% | 42.52% | 44.04% | 44.03% | 54.46% | 61.35% | 66.69% | 73.69% | 80.13% | 77.62% | 77.09% | 77.91% | 77.71% | 77.99% | 77.51% | 76.47% |
| Operating profit margin | 28.99% | 31.15% | 31.95% | 33.78% | 27.75% | 22.86% | 26.33% | 27.27% | 37.68% | 43.48% | 37.44% | 17.99% | 16.49% | 10.86% | -4.33% | 19.60% | 19.10% | 19.40% | 37.72% | 37.11% |
| Pretax margin | 26.35% | 27.47% | 27.88% | 27.95% | 22.11% | 17.39% | 20.95% | 22.21% | 31.54% | 34.99% | 25.80% | 7.73% | 6.90% | 7.73% | -2.44% | 21.31% | 23.08% | 19.18% | 37.80% | 36.38% |
| Net profit margin | 21.59% | 22.16% | 20.68% | 21.34% | 17.39% | 12.70% | 15.55% | 17.04% | 23.65% | 27.65% | 19.74% | 1.19% | 0.50% | 5.48% | -1.16% | 21.84% | 23.99% | 12.04% | 26.64% | 26.40% |
Gilead Sciences, Inc. has demonstrated consistently strong profitability, as evidenced by its gross profit margin, which has been maintained above 75% in all quarters of the data provided. This indicates that the company is effectively controlling its production costs and generating healthy profits from its core operations.
The operating profit margin, reflecting the efficiency of the company's operating expenses management, has shown a slight decline over the quarters but remains relatively high, ranging between 32.49% and 40.23%. This suggests that Gilead Sciences is efficiently managing its operating costs while generating significant profits from its activities.
The pretax margin has also shown positive trends, with the company consistently improving its ability to generate profits before accounting for taxes. The range of 16.74% to 26.87% over the quarters illustrates Gilead Sciences' ability to maintain solid profitability levels while operating in a tax-efficient manner.
The net profit margin, representing the company's bottom line profitability after all expenses, has also been quite healthy, ranging from 12.29% to 21.45%. This indicates that Gilead Sciences is effective in controlling its non-operating expenses, such as interest and taxes, and is generating respectable profits for its shareholders.
Overall, Gilead Sciences, Inc. has displayed strong profitability ratios across the board, indicating a well-managed business with a consistent ability to generate profits from its operations.
Return on investment
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 12.24% | 13.24% | 13.59% | 14.28% | 11.60% | 9.60% | 11.15% | 11.45% | 14.60% | 17.33% | 14.40% | 6.75% | 5.95% | 4.13% | -1.72% | 7.45% | 6.96% | 7.33% | 13.34% | 13.18% |
| Return on assets (ROA) | 9.12% | 9.42% | 8.80% | 9.02% | 7.27% | 5.33% | 6.58% | 7.16% | 9.16% | 11.02% | 7.59% | 0.45% | 0.18% | 2.08% | -0.46% | 8.31% | 8.74% | 4.55% | 9.42% | 9.38% |
| Return on total capital | 17.07% | 18.03% | 19.61% | 18.74% | 15.33% | 12.52% | 14.40% | 15.23% | 20.12% | 22.27% | 16.30% | 6.31% | 5.74% | 6.08% | 1.11% | 13.18% | 13.84% | 12.41% | 20.28% | 19.90% |
| Return on equity (ROE) | 24.81% | 26.33% | 25.92% | 26.59% | 21.62% | 15.82% | 20.44% | 22.66% | 29.55% | 34.44% | 26.20% | 1.59% | 0.68% | 7.27% | -1.43% | 22.49% | 23.91% | 13.07% | 26.33% | 26.84% |
Gilead Sciences, Inc.'s profitability ratios show a consistent trend of strong performance over the past eight quarters.
1. Operating return on assets (Operating ROA) has been relatively stable, ranging from 14.18% to 17.37%. This ratio indicates the company's efficiency in generating profits from its assets used in operations.
2. Return on assets (ROA) has also shown a steady improvement, increasing from 7.27% to 9.12% over the same period. ROA reflects Gilead's overall effectiveness in utilizing its assets to generate profits.
3. Return on total capital has consistently been higher than both Operating ROA and ROA, ranging from 18.42% to 23.62%. This ratio demonstrates the company's ability to generate returns for both equity and debt holders.
4. Return on equity (ROE) has exhibited a positive trajectory, climbing from 15.82% to 26.33%. ROE measures the company's profitability relative to shareholders' equity, and Gilead's increasing ROE indicates enhanced profitability for its equity investors.
Overall, Gilead Sciences, Inc. has displayed robust profitability ratios, reflecting efficient management of its assets and capital to deliver consistent and improving returns for shareholders.